Development of Macrocyclic Peptides as Modulators of G-protein Activity

webinar

Thu, 21 Apr 2022, 16:00 CEST (Berlin)

Prof. Dr. Diana Imhof, University of Bonn, Germany

Development of Macrocyclic Peptides as Modulators of G-protein Activity

Heterotrimeric G-proteins are important components of intracellular signal transduction, since G-proteins transmit information from an externally stimulated, membrane-bound G-protein-coupled receptor (GPCR) into the cell interior. The importance of these signaling cascades cannot be denied: More than 30% of the approved drugs address the extracellularly easily accessible GPCRs. Since the Gα subunit directly interacts with both the GPCR and the effectors, Gα plays a crucial role in GPCR signaling. This is reflected in the fact that signaling specificity is achieved through four distinct Gα subfamilies: Gαs, Gαi, Gαq, and Gα12/13, which mediate distinct signaling pathways in the cell. Considering the influence of G-proteins on (patho)physiological processes, tools to modulate the action of Gα proteins are of great interest for current pharmaceutical research. However, the direct targeting of intracellular Gα subunits by chemical agents still is a great challenge, since the activity of the compound must be combined with cell-penetrating properties.

Diana shall present an approach to combine (“wet”) high-throughput techniques with computational approaches to gain a deeper insight into potential binding sites, that can then be addressed for compound design. She will focus on the development of a first series of linear and cyclic peptides, which turned out to possess a GEM (guanine nucleotide exchange modulator)-like activity concerning the modulation of Gai and Gas proteins — this does provide new opportunities for intracellular targeting of GPCR-dependent signaling pathways.
Join Diana and us and learn about her latest GPCR research.

Current news

Entering The Trillion Era: AMBrosia Update
October 7, 2026 13:24 CEST
More chemistry. Trillions of possibilities. AMBrosia enters its third version with more than 2.4 trillion virtual product molecules. Developed in close collaboration with Ambinter (a brand of Greenpharma), the expanded Chemical Space combines 313,777 building blocks through 54 chemical reactions, implemented as 131 technical reactions, opening up a wealth of...
Read on
category
Events
DrugSpace 2026 Symposium - The Path to Digital Chemistry
October 6, 2026 11:28 CEST
Where Medicinal and Computational Chemistry Come Together We are delighted to invite drug hunters, compound enthusiasts, and molecule designers back to the virtual DrugSpace Symposium. The fifth edition takes place on December 9, 2026, under the theme “The Path to Digital Chemistry,” and turns the spotlight on where computational and...
Read on
category
Events
BioSolveIT at the Enamine Drug Discovery Conference 2026 in Riga
September 23, 2026 16:21 CEST
The Enamine Drug Discovery Conference in Riga (Latvia) comes to a close today. Our CEO Dr. Christian Lemmen and our SVP Application Science Dr. Marcus Gastreich spent the past four days, 20 to 23 September 2026, at the Radisson Blu Latvija Conference & Spa Hotel, and they return with much...
Read on